TCT 910: Novel Hybrid Drug-Eluting BioStealth™ Stent for Below-the-Knee Lesions: Preclinical Results and Proposed Pivotal Clinical Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Stryker Corporation</li><li> - Global Vascular</li></ul>